» Articles » PMID: 20180942

Antifibrotic Activity of an Inhibitor of Histone Deacetylases in DOCA-salt Hypertensive Rats

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2010 Feb 26
PMID 20180942
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Histone deacetylases (HDACs) silence genes by deacetylating lysine residues in histones and other proteins. HDAC inhibitors represent a new class of compounds with anti-inflammatory activity. This study investigated whether treatment with a broad spectrum HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), would prevent cardiac fibrosis, part of the cardiovascular remodelling in deoxycorticosterone acetate (DOCA)-salt rats.

Experimental Approach: Control and DOCA-salt rats were treated with SAHA (25 mg x kg(-1) x day(-1) s.c.) for 32 days. Changes in cardiovascular structure and function were assessed by blood pressure in vivo and in Langendorff perfused hearts, ventricular papillary muscle and in aortic rings in vitro. Left ventricular collagen deposition was assessed by histology.

Key Results: Administration of SAHA to DOCA-salt rats attenuated the following parameters: the increased concentration of over 20 pro-inflammatory cytokines in plasma, increased inflammatory cell infiltration and interstitial collagen deposition, increased passive diastolic stiffness in perfused hearts, prolongation of action potential duration at 20% and 90% of repolarization in papillary muscle, development of left ventricular hypertrophy, systolic hypertension and changes in vascular dysfunction.

Conclusions And Implications: The HDAC inhibitor, SAHA, attenuated the cardiovascular remodelling associated with DOCA-salt hypertensive rats and improved cardiovascular structure and function, especially fibrosis, in the heart and blood vessels, possibly by suppressing inflammation. Control of cardiac histone or non-histone protein acetylation is a potential therapeutic approach to preventing cardiac remodelling, especially cardiac fibrosis.

Citing Articles

Epigenetic DNA Methylation and Protein Homocysteinylation: Key Players in Hypertensive Renovascular Damage.

Ren L, Pushpakumar S, Almarshood H, Das S, Sen U Int J Mol Sci. 2024; 25(21).

PMID: 39519150 PMC: 11546175. DOI: 10.3390/ijms252111599.


Role of histone deacetylase inhibitors in non-neoplastic diseases.

Zhou C, Zhao D, Wu C, Wu Z, Zhang W, Chen S Heliyon. 2024; 10(13):e33997.

PMID: 39071622 PMC: 11283006. DOI: 10.1016/j.heliyon.2024.e33997.


The Role of Selected Epigenetic Pathways in Cardiovascular Diseases as a Potential Therapeutic Target.

Wolowiec A, Wolowiec L, Grzesk G, Jasniak A, Osiak J, Husejko J Int J Mol Sci. 2023; 24(18).

PMID: 37762023 PMC: 10531432. DOI: 10.3390/ijms241813723.


The Current Therapeutic Role of Chromatin Remodeling for the Prognosis and Treatment of Heart Failure.

Kraus L, Beavens B Biomedicines. 2023; 11(2).

PMID: 36831115 PMC: 9953583. DOI: 10.3390/biomedicines11020579.


Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis.

Sehgal M, Jakhete S, Manekar A, Sasikumar S Heliyon. 2022; 8(8):e09773.

PMID: 36061031 PMC: 9434059. DOI: 10.1016/j.heliyon.2022.e09773.


References
1.
Adcock I . HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol. 2007; 150(7):829-31. PMC: 2013887. DOI: 10.1038/sj.bjp.0707166. View

2.
Zalewski A, Shi Y . Vascular myofibroblasts. Lessons from coronary repair and remodeling. Arterioscler Thromb Vasc Biol. 1997; 17(3):417-22. DOI: 10.1161/01.atv.17.3.417. View

3.
Halili M, Andrews M, Sweet M, Fairlie D . Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem. 2009; 9(3):309-19. DOI: 10.2174/156802609788085250. View

4.
Lin H, Hu C, Chan H, Liew Y, Huang H, Lepescheux L . Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol. 2007; 150(7):862-72. PMC: 2013883. DOI: 10.1038/sj.bjp.0707165. View

5.
Loch D, Hoey A, Morisseau C, Hammock B, Brown L . Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys. 2007; 47(1):87-98. PMC: 1892223. DOI: 10.1385/cbb:47:1:87. View